See more : MY EG SERVICES BHD (MYYGF) Income Statement Analysis – Financial Results
Complete financial analysis of Caliway Biopharmaceuticals Co., Ltd. (6919.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Caliway Biopharmaceuticals Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- K Pharma,Inc. (4896.T) Income Statement Analysis – Financial Results
- Tronox Holdings plc (TROX) Income Statement Analysis – Financial Results
- CRYPTOL.ASSET GRP EO 0,05 (CAP.DE) Income Statement Analysis – Financial Results
- Pacific Booker Minerals Inc. (PBMLF) Income Statement Analysis – Financial Results
- Mukat Pipes Limited (MUKATPIP.BO) Income Statement Analysis – Financial Results
Caliway Biopharmaceuticals Co., Ltd. (6919.TWO)
About Caliway Biopharmaceuticals Co., Ltd.
Caliway Biopharmaceuticals Co.Ltd develops small molecule drugs for medical aesthetic and inflammatory disease. The company was founded in 2012 and is based in New Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 38.93M | 12.82M | 12.34M | 10.35M | 18.65M |
| Cost of Revenue | 11.46M | 3.21M | 3.11M | 3.68M | 7.84M |
| Gross Profit | 27.47M | 9.61M | 9.23M | 6.68M | 10.81M |
| Gross Profit Ratio | 70.56% | 74.94% | 74.83% | 64.49% | 57.96% |
| Research & Development | 503.99M | 295.02M | 180.62M | 88.98M | 109.14M |
| General & Administrative | 36.89M | 34.21M | 46.52M | 23.29M | 23.78M |
| Selling & Marketing | 61.00K | 5.00K | 12.83M | 8.00K | 25.00K |
| SG&A | 36.95M | 34.21M | 59.35M | 23.29M | 23.80M |
| Other Expenses | 8.10M | 28.95M | 9.27M | 11.67M | -122.13M |
| Operating Expenses | 540.94M | 329.23M | 239.97M | 112.28M | -122.13M |
| Cost & Expenses | 552.40M | 332.44M | 243.07M | 115.95M | -122.13M |
| Interest Income | 17.42M | 5.19M | 99.00K | 38.00K | 24.00K |
| Interest Expense | 498.00K | 668.00K | 2.90M | 4.51M | 3.69M |
| Depreciation & Amortization | 27.87M | 25.34M | 23.28M | 18.21M | 15.44M |
| EBITDA | -460.09M | -260.15M | -198.09M | -94.43M | -106.70M |
| EBITDA Ratio | -1,181.78% | -2,029.27% | -1,605.37% | -731.25% | -654.87% |
| Operating Income | -487.96M | -285.49M | -221.36M | -105.60M | -122.13M |
| Operating Income Ratio | -1,253.36% | -2,226.89% | -1,793.99% | -1,020.30% | -654.87% |
| Total Other Income/Expenses | -498.00K | -668.00K | -2.90M | 7.20M | 331.00K |
| Income Before Tax | -488.46M | -286.16M | -224.26M | -98.40M | -121.80M |
| Income Before Tax Ratio | -1,254.64% | -2,232.10% | -1,817.52% | -950.72% | -653.10% |
| Income Tax Expense | 0.00 | 0.00 | 30.00K | 86.00K | 31.00K |
| Net Income | -488.46M | -286.16M | -224.29M | -98.49M | -121.83M |
| Net Income Ratio | -1,254.64% | -2,232.10% | -1,817.76% | -951.56% | -653.27% |
| EPS | -3.94 | -2.44 | -4.87 | -1.85 | -2.28 |
| EPS Diluted | -3.94 | -2.44 | -4.87 | -1.85 | -2.28 |
| Weighted Avg Shares Out | 123.89M | 117.13M | 46.07M | 53.35M | 53.35M |
| Weighted Avg Shares Out (Dil) | 123.89M | 117.13M | 46.07M | 53.35M | 53.35M |
No news found for: 6919.TWO
Source: https://incomestatements.info
Category: Stock Reports